Zhejiang Huahai Pharmaceutical issues convertible bond put-back notice, updates on lawsuit

Zhejiang Huahai Pharmaceutical (SSE:600521) announced a second optional put-back period for its "Huahai convertible bonds" (bond code: 110076), allowing bondholders to sell back their bonds at a price of yuan 100.30 per bond, inclusive of accrued interest and tax. The put-back period is scheduled from 2025-12-22 to 2025-12-26, with funds to be distributed by 2025-12-31. During this period, "Huahai convertible bonds" will cease to be convertible to shares.

Separately, the company provided an update on the "Gaston Roberts case," an ongoing personal injury lawsuit where the plaintiff has appealed an initial judgment that favored the company. This case is part of broader litigation related to valsartan raw materials, with the company noting that the appeal process has just begun.

Zhejiang Huahai Pharmaceutical stated that it cannot yet determine the impact of the Gaston Roberts case appeal on its financial results. Investors are cautioned to be aware of the investment risks associated with the convertible bond put-back, as the current market price of "Huahai convertible bonds" is higher than the put-back price.